Using bisphenol-a to study the onset of polycystic ovarian syndrome

Other OA: gold CC-BY-4.0
⚙ AI-generated summary by qwen3.7-flash+body, 2026-10-15 ⓘ

Neonatal exposure to bisphenol A in rats induces polycystic ovarian syndrome-like traits including elevated androgens, altered ovarian morphology, and impaired fertility, providing a model for studying the disorder's onset.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-15 · read from full text ⓘ

This review discusses the use of neonatal bisphenol-A exposure in rats as a model for investigating the onset of polycystic ovarian syndrome. The authors highlight findings that such exposure leads to elevated androgen levels, altered GnRH pulsatility, ovarian cysts, and significant fertility impairment in adult females. A key limitation noted is that this specific animal model does not replicate the metabolic dysfunction, such as obesity, commonly seen in human PCOS cases. Relevance to endometriosis: Endometriosis is cited in the introduction as one of several diseases linked to endocrine-disrupting chemicals, but the paper's primary focus remains on polycystic ovarian syndrome.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 9,311 characters · extracted from oa-doi-fallback · 2 sections · click to expand

References

1 BarontiniM.Garcia-RudazM. C.VeldhuisJ. D. (2001). Mechanisms of hypothalamic-pituitary-gonadal disruption in polycystic ovarian syndrome. Arch. Med. Res.32, 544–552. 2 BlankS. K.McCartneyC. R.HelmK. D.MarshallJ. C. (2007). Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty. Semin. Reprod. Med.25, 352–359. 3 Diamanti-KandarakisE.BourguignonJ. P.GiudiceL. C.HauserR.PrinsG. S.SotoA. M.ZoellerR. T.GoreA. C. (2009). Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr. Rev.30, 293–342. 4 EaglesonC. A.GingrichM. B.PastorC. L.AroraT. K.BurtC. M.EvansW. S.MarshallJ. C. (2000). Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J. Clin. Endocrinol. Metab.85, 4047–4052. 5 FernandezM.BianchiM.Lux-LantosV.LibertunC. (2009). Neonatal exposure to bisphenol a alters reproductive parameters and gonadotropin releasing hormone signaling in female rats. Environ. Health Perspect.117, 757–762. 6 FernandezM.BourguignonN.Lux-LantosV.LibertunC. (2010). Neonatal exposure to bisphenol a and reproductive and endocrine alterations resembling the polycystic ovarian syndrome in adult rats. Environ. Health Perspect.118, 1217–1222.10.1289/ehp.0901257 7 KandarakiE.ChatzigeorgiouA.LivadasS.PaliouraE.EconomouF.KoutsilierisM.PalimeriS.PanidisD.Diamanti-KandarakisE. (2011). Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. J. Clin. Endocrinol. Metab.96, E480–E484. 8 RichterC. A.BirnbaumL. S.FarabolliniF.NewboldR. R.RubinB. S.TalsnessC. E.VandenberghJ. G.Walser-KuntzD. R.vom SaalF. S. (2007). In vivo effects of bisphenol A in laboratory rodent studies. Reprod. Toxicol.24, 199–224. 9 Sotomayor-ZarateR.DorfmanM.ParedesA.LaraH. E. (2008). Neonatal exposure to estradiol valerate programs ovarian sympathetic innervation and follicular development in the adult rat. Biol. Reprod.78, 673–680. 10 TsutsumiR.WebsterN. J. (2009). GnRH pulsatility, the pituitary response and reproductive dysfunction. Endocr. J.56, 729–737. Summary

Keywords

bisphenol A, Endocrine disrupting chemical, Fertility, GnRH, Polycystic ovarian syndrome Citation Klenke U and Hutchins BI (2011) Using Bisphenol-A to Study the Onset of Polycystic Ovarian Syndrome. Front. Endocrin. 2:12. doi: 10.3389/fendo.2011.00012 Received 31 March 2011 Accepted 29 April 2011 Published 10 May 2011 Volume 2 - 2011 Copyright © 2011 Klenke and Hutchins. This is an open-access article subject to a non-exclusive license between the authors and Frontiers Media SA, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and other Frontiers conditions are complied with. *Correspondence: [email protected]; [email protected] †Ulrike Klenke and B. Ian Hutchins have contributed equally to this work. This article was submitted to Frontiers in Neuroendocrine Science, a specialty of Frontiers in Endocrinology. Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-11-08T09:52:27.483963+00:00
pubmed
last seen: 2026-10-08T21:10:28.861444+00:00
unpaywall
last seen: 2026-05-21T05:10:58.409756+00:00
License: CC-BY-4.0